A5060651716- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Nanowire Synthesis and Applications
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Biosimilars and Bioanalytical Methods
- Cytomegalovirus and herpesvirus research
- Sarcoma Diagnosis and Treatment
- Adolescent and Pediatric Healthcare
- COVID-19 Impact on Reproduction
- CNS Lymphoma Diagnosis and Treatment
- Ion Channels and Receptors
- Immune cells in cancer
- Neurofibromatosis and Schwannoma Cases
- Cancer-related Molecular Pathways
- Multiple Myeloma Research and Treatments
University of Pennsylvania
2017-2024
Peter MacCallum Cancer Centre
2023-2024
The Royal Melbourne Hospital
2024
The University of Melbourne
2023-2024
Alfred Health
2015-2023
University of Minnesota
2023
Abramson Cancer Center
2020
Palmetto Hematology Oncology
2020
Australian Centre for HIV and Hepatitis Virology Research
2019
Monash University
2014-2019
Abstract Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two thirds of experience treatment failure. Resistance apoptosis is a key feature cancer cells, and it associated In 87 NHL treated anti-CD19 CART, we found that chromosomal alteration 2 (BCL-2), critical antiapoptotic regulator, cells was reduced survival. Therefore, combined CART19 the FDA-approved BCL-2...
The approval of the anti-CD19 chimeric antigen receptor (CAR) T-cell product tisagenlecleucel (Kymriah®) by US Food and Drug Administration (FDA) European Medicines Agency (EMA) for relapsed pediatric B-lineage acute lymphoblastic leukemia (B-ALL) was a landmark event in therapy. based on data from phase II global trial which 75 young adult B-ALL patients received tisagenlecleucel, demonstrating safety, feasibility biological response, with complete remissions (CR) at three months 81%...
Children and adults with Philadelphia chromosome-like B cell acute lymphoblastic leukemia (Ph-like B-ALL) experience high relapse rates despite best-available conventional chemotherapy. Ph-like ALL is driven by genetic alterations that activate constitutive cytokine receptor kinase signaling, early-phase trials are investigating the potential of addition tyrosine inhibitors (TKIs) to chemotherapy improve clinical outcomes. However, preclinical studies have shown JAK or PI3K pathway...
Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) chronic phase myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, although the incidence of these events is well described, response to therapy dose modifications on not been comprehensively characterized real-world setting. We retrospectively reviewed dasatinib adverse 212 patients at 17...
Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses chronic myeloid leukemia phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk vascular AEs (VAEs) other TKIs, although natural history these events response to dose modifications or cessation has not...
Abstract Background Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that often develop in patients with neurofibromatosis type 1 (NF1). To address the critical need for novel therapeutics MPNST, we aimed to establish an ex vivo 3D platform accurately captured genomic diversity of MPNST and could be utilized a medium-throughput manner drug screening studies validated using patient-derived xenografts (PDX). Methods Genomic analysis was performed on all...
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis 78 from 19 hospitals across Australia and New Zealand, treated over last 15 years with "off-the-shelf" allogeneic T cells directed combination Epstein–Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus (BKV), John Cunningham (JCV) and/or adenovirus (AdV) under Australian Therapeutic...
A 55-year-old man with a history of well controlled HIV infection was admitted acute renal impairment, peripheral oedema, constitutional symptoms, deranged liver function and hypercalcaemia. Core biopsies retroperitoneal mass demonstrated anaplastic lymphoma kinase (ALK) negative large cell (ALCL) unusual Paired box 5 (PAX5) positivity. The same malignant cells were identifiable on urine cytology. Staging investigations revealed extensive nodal extranodal disease including ALK ALCL involving...
Sorafenib priming may augment salvage chemotherapy in relapsed
Abstract Despite recent advances in T cell immunotherapy for the treatment of human cancer, metastatic solid tumors remain an intractable challenge. Macrophages are usually most abundant immune tumor microenvironment (TME) where, as immunosuppressive tumor-associated macrophages (TAMs), they participate disease progression. The current goals macrophage-based immunotherapies to reduce TAM infiltration or enhance phagocytosis. In contrast, we have developed a new paradigm based on adoptive...
A 55-year-old woman was referred to the Respiratory outpatient department for consideration of a lung transplant, indicated end-stage chronic obstructive pulmonary disease. As part her work up, full blood count (FBC) and film were performed, latter demonstrating striking number Howell-Jolly bodies, as well expected target cells acanthocytes (top). The FBC also showed haemoglobin concentration 98 g/l, white cell 7·9 × 109/l platelet 299 109/l. lymphocyte normal. Routine high-resolution...
Abstract One of the main challenges currently faced in ovarian cancer treatment is that primary platinum/taxane therapy used to treat patients does not meaningfully extend survival. The overall survival for with advanced disease less than 30% most recurring within 5 years initial therapy. Once resistant develops there are few second line options, which inevitably leads progression. Thus, a critical need identify new therapies can overcome chemoresistance and produce meaningful increases...